Plain-English translation of NCT07348302 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called sublingual MM09, which you place under your tongue daily to treat allergies caused by dust mites. The study will compare this new medication to a placebo (a dummy treatment with no active ingredient) over 12 months. Researchers want to see if the medication can reduce sneezing, congestion, itchy eyes, and other allergy symptoms in people aged 12 to 65.
Many people suffer from dust mite allergies that don't improve enough with standard allergy medicines alone. This trial is testing whether this new under-the-tongue treatment could offer a better, longer-lasting solution by training your immune system to become less sensitive to dust mites.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic for a baseline evaluation, then take the medication (or placebo) as a few drops under your tongue once daily for 12 months. During this time, you would use your smartphone to log your allergy symptoms and any allergy medications you take. You would return to the clinic periodically so researchers can monitor how you're doing and check for any side effects. At the end of the 12 months, your symptoms would be compared to those of participants who received the placebo to see if the new treatment worked.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Argentina